The Stem Cells 2019 Conference participants will get an opportunity to learn new tools, technologies, and discoveries; will encourage and promote collaboration; to identify hurdles that slow the development of advanced therapy; and career development of young researchers at the platform of Hilaris Conferences. The Regenerative Medicine 2019 Conference programme will include keynote/plenary sessions, industrial and academics talks, specific workshops, symposia, young scholars forum, video presentations, and exciting discussions.
The Stem Cells 2019 Congress will be covering diverse topics of stem cell and regenerative medicine such as advances in stem cells and their niches, stem cells in regenerative therapies, stem cells in disease modelling and drug development, technologies in stem cell science, stem cells in disease, cancer stem cells, gene therapy, biomaterials, tissue engineering, pluripotency and reprogramming, repair and regeneration, regulatory issues, translation and commercialization.
Hilaris Conferences believes that access to science is essential to sustainable development and this platform will surely establish collaboration among the researchers, policymakers, innovators, investors and industry. Hilaris Meetings seeks the support of participants for the vision Together towards tomorrow.
Hilaris Conferences is hosting international Conferences, Meetings, Events, Workshops, and Symposium in the areas of Life Sciences, Clinical and Medical Sciences, Healthcare, Agriculture & Food, Pharmaceuticals, Environmental Sciences, and Applied Engineering across the world. We welcome participants to join our meetings to share and exchange knowledge for a better future.
The Stem Cells and Regenerative Medicine 2019 will gather international participants in Berlin Germany. This platform will provide an opportunity for academic and industry researchers, clinicians, investors and innovators to contemplate and establish new insights and developments in the area of stem cells, regenerative medicine, tissue engineering, gene therapy, biobanking, biomaterials and allied areas.
Scope/ Target Audience for Stem Cells Regenerative Medicine 2019 Berlin, Germany
Participants from Industry:
Stem Cells Regenerative Medicine Conference welcomes Industry Researchers, Chief Executive Officers, Directors, Chief Scientific Officers, Chief Medical Officers, Head of Regulatory Affairs, Chief Operating Officer, Head of Legal & Intellectual Property, Research Heads, Consultants, Business Development & Sales Teams, Policymakers, Investors, Government Officials and other participants from:
- Stem Cell Research Companies
- Stem Cell Therapy Companies
- Stem Cell Banking Companies
- Stem Cell Technology & Instrument Provider Companies
- Wound Care Companies
- Regenerative Therapeutics & Diagnostic Device Companies
- Gene Therapies Companies
- Regenerative Medicine Companies
- Biomaterial Companies
- Solution Provider Companies
- CROs/CMOs
- and many pharma companies are using regenerative medicine research studies for drug/therapy developments are from the field of oncology, orthopaedic, wound healing, dermatology, neurodegenerative diseases, cardiovascular, and also in diabetes for a better cure.
Participants from Academia/Universities/Hospitals:
Stem Cells Regenerative Medicine 2019 Conference welcomes Directors, Deans, Lab Heads, Scientists, Clinicians and Students, with an interest towards stem cells, regenerative medicine, gene therapy, tissue engineering, biobanking and biomaterial, but are not limited to:
- Advances in Stem Cells and Their Niches
- Cancer Stem Cells
- Stem Cells in Diseases
- Stem Cells in Regenerative Therapies
- Pluripotency and Reprogramming
- Repair and Regeneration
- Artificial Organ Transplantation
- Rejuvenation
- Stem Cell Therapy
- Stem Cell Genetics
- Hematopoietic Stem Cells
- Stem Cell Treatments
- Stem Cells in Disease Modeling and Drug Development
- Scaffolds in Regenerative Medicine
- Computational Stem Cell Biology
- Technologies in Stem Cell Research
- Biobanking
- Biomaterials
- Clinical Trials and Regulatory Affairs
- and New Trends in Stem Cell Research
The regenerative medicine mainly uses stem cells to repair, replace, and regenerate tissues and organs affected by damage, disease, or ageing by restoring its normal function. These regenerative medicine market by the application are oncology, orthopaedic and musculoskeletal spine, wound healing, dermatology, neurodegenerative diseases, cardiovascular, and also in diabetes. The pluripotency and reprograming capability of stem cells increase the importance in this field. The global regenerative medicine market was valued at $5,444 million in 2016 and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023.
The factors driving the growth of the regenerative medicine market include the emergence of stem cell technology, rise in the incidence of degenerative diseases, and very fewer availability of organs for transplantation. Increase in focus on stem cells and growth in R&D activities in emerging economies are expected to supplement the market growth. The developing nations are focused on technological advancements, which is expected to boost market growth, globally. However, stringent government regulations, operational inefficiency, and the high cost of treatment through regenerative medicine are estimated to hamper the growth of the market.
The leading companies (from 650+) associated in the field of regenerative medicine, stem cell, and cell therapy market across the globe are Anika Therapeutics Inc., Arthrex Inc., BioTime, Inc., BioSpherix Ltd., Baxter International Inc., Celgene Corporation, Cellink AB, RegenHU Ltd, Cosmo Bio Co. Ltd, CONMED Corporation, Cytori Therapeutics Inc., DePuy Synthes Inc., Invitrx Therapeutics, Japan Tissue Engineering Co. Ltd, Kite Pharma, Living Cell Technologies, Mocida Pharceuticals Co. Ltd, Medtronic Inc., Nita Gelatin Inc, Smith & Nephew plc, Stryker Corporation, RepliCel Life Sciences Inc., Medeor Therapeutics, Mesoblast Limited, Osiris Therapeutics Inc., Regeneus, Tissue Regenix, Takeda Pharmaceutical Company Limited, Cell Source, StemCells Inc., Vericel Corporation, Vertex Pharmaceuticals Inc., Zimmer Holdings Inc., Corning B.V. Life Sciences, Miltenyi Biotec GmbH, STEMCELL Technologies GmbH, Takara, BD Biosciences, Bioquell UK Ltd, BioSpherix, Ltd, ChemoMetec GmbH, Cygenia, I&L Biosystems, Lonza, Maco Pharma, neoFroxx GmbH, PromoCell, ReproCELL, Jellagen, Manchester BioGel, Merck, Pfizer, Sanofi, Tissue Solution, Applied StemCell, NovaBiomedical, Celixir, CellGenix, PluriCell, PluriStem, Sigilon, AgeX Therapeutics, ECM Therapeutics Inc., Theracell, Advancells, Orgenesis, ReeLabs, BioRestorative Therapies and CellBox Solution.
